Endometrial Mucinous Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: A primary, usually low grade adenocarcinoma of the endometrium in which the majority of the malignant epithelial cells contain abundant intracytoplasmic mucin. 
Endometrial mucinous adenocarcinomas most frequently harbor alterations in TP53, PTEN, PIK3CA, and KRAS .
TP53 c.217-c.1178 Missense, TP53 Mutation, TP53 Missense, TP53 P190L, and TP53 Exon 7 Mutation are the most common alterations in endometrial mucinous adenocarcinoma .
There are 2 clinical trials for endometrial mucinous adenocarcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain endometrial mucinous adenocarcinoma as an inclusion criterion, 2 are phase 2 (2 open).
ER and PR are the most frequent gene inclusion criteria for endometrial mucinous adenocarcinoma clinical trials .
Abemaciclib, atezolizumab, and bevacizumab are the most common interventions in endometrial mucinous adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.